Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation

Biologics have become an important component of treatment strategies for a variety of diseases, but the immunogenicity of large immune complexes (ICs) and aggregates of biologics may increase risk of adverse events is a concern for biologics and it remains unclear whether large ICs consisting of int...

Full description

Bibliographic Details
Main Authors: Masanao Kyuuma, Ayaka Kaku, Chiemi Mishima-Tsumagari, Bunichiro Ogawa, Mayumi Endo, Yunoshin Tamura, Kei-ichiro Ishikura, Masashi Mima, Yutaka Nakanishi, Yasuyuki Fujii
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
tumor necrosis factor
VHH
rheumatoid arthritis
injection site reaction
immunogenicity
Fcγ receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1149874/full

Similar Items

Similar Items